Patents by Inventor Raphaël Faucard

Raphaël Faucard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antiretroviral drug targeting human endogenous retrovirus
    Patent number: 10894820
    Abstract: The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: January 19, 2021
    Assignee: GENEURO SA
    Inventors: Herve Perron, Francois Curtin, Alois Lang, Raphael Faucard, Julie Medina, Alexandra Madeira, Nadege Gehin
  • Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein
    Patent number: 10752675
    Abstract: The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: August 25, 2020
    Assignee: GENEURO S.A.
    Inventors: Herve Perron, Reza Firouzi, Patrick Küry, Raphaël Faucard, Alexandra Madeira, Julie Joanou
  • Antiretroviral Drug Targeting Human Endogenous Retrovirus
    Publication number: 20190263895
    Abstract: The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.
    Type: Application
    Filed: March 22, 2019
    Publication date: August 29, 2019
    Inventors: Herve Perron, Francois Curtin, Alois Lang, Raphael Faucard, Julie Medina, Alexandra Madeira, Nadege Gehin
  • COMPOUNDS FOR TREATING THE REMYELINATION BLOCKADE IN DISEASES ASSOCIATED WITH THE EXPRESSION OF HERV-W ENVELOPE PROTEIN
    Publication number: 20180066040
    Abstract: The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 8, 2018
    Applicant: GENEURO S.A.
    Inventors: Herve PERRON, Reza FIROUZI, Patrick KÜRY, Raphaël FAUCARD, Alexandra MADEIRA, Julie JOANOU
  • Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein
    Patent number: 9840550
    Abstract: The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: December 12, 2017
    Assignee: GENEURO S.A.
    Inventors: Hervé Perron, Reza Firouzi, Patrick Küry, Raphaël Faucard, Alexandra Madeira, Julie Joanou
  • Antiretroviral Drug Targeting Human Endogenous Retrovirus
    Publication number: 20170101461
    Abstract: The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.
    Type: Application
    Filed: May 27, 2015
    Publication date: April 13, 2017
    Inventors: Herve Perron, Francois Curtin, Alois Lang, Raphael Faucard, Julie Medina, Alexandra Madeira, Nadege Gehin
  • COMPOUNDS FOR TREATING THE REMYELINATION BLOCKADE IN DISEASES ASSOCIATED WITH THE EXPRESSION OF HERV-W ENVELOPE PROTEIN
    Publication number: 20150218256
    Abstract: The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.
    Type: Application
    Filed: October 1, 2013
    Publication date: August 6, 2015
    Inventors: Hervé Perron, Reza Firouzi, Patrick Küry, Raphaël Faucard, Alexandra Madeira, Julie Joanou